Loading asset research
Altimmune Inc. Common Stock
ALTNasdaq · USD · StocksQuote as of · Exchange session not verified$3.27
-0.61%
Today
ALT
Loading 1D prices…
Market cap
$636.1M
Volume
2.7M
52w high
$6.4452w low
$2.56Company profile
Altimmune Inc. Common Stock
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Gaithersburg, MD, United States
Employees
57
Fiscal year end
1231
CIK
1326190
Session & valuation
Open$3.33
Previous close$3.29
Day high$3.41
Day low$3.26
30-day avg. volume4.2M
Outstanding shares194.5M
Diluted EPS-$1.00
Latest annual period
P/E (trailing)-3.27
P/E (forward)-4.89
Price / book1.34
Beta0.18
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| STTKShattuck Labs Inc. Common Stock | $622.3M | $1M | -4880.90% | -$0.70 | +0.81% | Buy |
| DRUGBright Minds Biosciences Inc. Common Stock | $619.9M | — | — | -$1.78 | -2.80% | Buy |
| EVOEvotec SE American Depositary Shares | $614.8M | — | — | -$0.29 | -2.26% | Hold |
| VSTMVerastem Inc. Common Stock | $662.9M | $30.9M | -677.59% | -$3.02 | -3.74% | Buy |
| CRMDCorMedix Inc. Common Stock | $609.9M | $311.7M | +52.31% | $2.04 | -1.76% | Buy |